FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| STATEMENT | OF CHANGES | S IN BENEFICIAL | . OWNERSHIP |
|------------------|------------|-----------------|-------------|

| | OMB APPRO | VAL | | | | | | |
|--------------------------|---------------------|-----------|--|--|--|--|--|--|
| | OMB Number: | 3235-0287 | | | | | | |
| Estimated average burden | | | | | | | | |
| | hours per response: | 0.5 | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person* <u>LPH II Investments Ltd</u> | | | | | | 2. Issuer Name and Ticker or Trading Symbol WINDTREE THERAPEUTICS INC /DE/ [| | | | | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) | | | | | |
|---|--------|------------|---|--------------|-----------------|--|--|--|---|-----|---|---|-------------------------------------|--|---------------------------------------|--|--------------|------------|--|
| | | | | | | WINT] | | | | | | | | Directo | r | X | 10% Ov | vner | |
| (Last) (First) (Middle) | | | | - <u>L''</u> | 1111 | 1 | | | | | | Officer below) | (give title | | Other (s below) | specify | | | |
| UNIT 110-111, BIO-INFO CTR, #2 SCIENCE | | | | | | 3. Date of Earliest Transaction (Month/Day/Year) | | | | | | | | | | | | | |
| PARK AVE HONG KONG SCIENCE PARK | | | | | 14 | 2/21/2 | 2018 | | | | | | | | | | | | |
| TARK AVE HUNG KUNG SCIENCE PARK | | | | | 4. | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | 6. Individual or Joint/Group Filing (Check Applicable | | | | | |
| (Street) | | | | | 04 | 4/06/2 | 2018 | | | | | | Lin | • | | | | | |
| SHATIN | K | 3 | | | | | | | | | | | | | • | | rting Persor | | |
| | | | | | - | | | | | | | | | Form fi Person | | e than | One Repor | ting | |
| (City) | (St | ate) | (Zip) | | | | | | | | | | | | | | | | |
| | | Ta | ble I - No | n-Der | ivativ | ve S | ecurities | s Ac | quired, | Dis | sposed o | f, or Be | neficial | y Owned | | | | | |
| 1. Title of Security (Instr. 3) 2. Transa Date (Month/D | | | | | Execution Date, | | Date, | 3. Transaction Code (Instr.) 8) 4. Securities Acquired (A) o Disposed Of (D) (Instr. 3, 4 a) | | | | Beneficia Owned Fo | Form lly (D) (D) (D) (I) (I) (I) | | Direct Indirect Istr. 4) | 7. Nature of Indirect Beneficial Ownership | | | |
| | | | | | | | | | | v | Amount | (A) or (D) | Price | Reported Transaction (Instr. 3 a | tion(s) | | | (Instr. 4) | |
| Common Stock 12/21/ | | | | 1/201 | /2018 | | P | | 1,810,938 A \$ | | \$3.3 | 2,352,605(1)(2) | | | D | | | | |
| | | | Table II - | | | | | | | | osed of, convertil | | | Owned | | | , | • | |
| 1. Title of Derivative Conversion Security (Instr. 3) 2. Conversion Date (Month/Day/Year) 3. Transaction Date Execution Date, if any (Month/Day/Year) | | Date, | 4. Transaction Code (Instr. 8) | | n Derivative | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s | s Illy | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | Beneficial Ownership (Instr. 4) | | | | |
| | | | | | | | | | | | | | Amount | 1 | (Instr. 4) | UII(S) | | | |
| | | | | | Code | v | (A) | (D) | Date Exercisab | | Expiration Date | Title | Number of Shares | | | | | | |
| Series F Warrants ⁽²⁾ | \$3.68 | 12/21/2018 | | | P | | 307,859 | | 12/24/201 | 18 | 05/24/2020 | Common Stock | 307,85 | \$0 | 1,040,8 | 886 | D | | |
| Series G Warrants ⁽²⁾ | \$4.05 | 12/21/2018 | | | P | | 597,610 | | 12/24/201 | 18 | 12/24/2023 | Common Stock | 597,61 | \$0 | 1,040,8 | 386 | D | | |

Explanation of Responses:

1. On December 22, 2017, the Issuer effected a 1-20 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

2. Effective December 21, 2018 the Issuer entered into a Securities Purchase Agreement with certain investors ("Investors") (the "Financing") whereby LPH II Investments Limited ("LPH II"), a wholly owned subsidiary of the Reporting Person, converted \$6.0 million of existing debt obligations in the Financing on the same terms as the Investors. The Issuer issued and LPH II received (i) 1,810,938 shares of Common Stock (ii) 307,859 Series F Warrants to purchase 307,859 shares of Common Stock at an exercise price of \$3.68 per share and (iii) 597,610 Series G Warrants (with the Series F Warrants the "Financing Warrants") to purchase 597,610 shares of Common Stock at an exercise price of \$4.05 per share. Accordingly, LPH II is deemed to beneficially own (i)1,810,938 shares of Common Stock (ii) 307,859 shares of Common Stock issuable upon exercise of the Series F Warrants and (iii) 597,610 shares of Common Stock issuable upon exercise of the Series G Warrants.

/s/ Ms. Lee Siu Fong

12/26/2018

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.